EVALUATE THE EFFECTS OF ANTIEPILEPTIC DRUGS ON REPRODUCTIVE ENDOCRINE SYSTEM IN NEWLY DIAGNOSED FEMALE EPILEPTIC PATIENTS RECEIVING EITHER VALPROATE OR LAMOTRIGINE MONOTHERAPY

This study has been conducted to analyze the growth of reproductive endocrine alteration in women suffering from epilepsy originating on either VPA (Valproate) or LTG (amotrigine) monotherapy. Hormonal reproductive profiles, ovarian morphology, hirsutism by ultrasonography and data about the menstrual cycle, specifically in newly identified epilepsy suffered women taking VPA (n=34) or secondly LTG (n=32) with the mono-therapy comparison. There are no women who were getting hormonal contraception. All patients described the frequency, type of seizure and their medical history. We also measure fasting insulin, body weight, dehydroepiandrosterone sulfate (DHEAS), testosterone, androstenedione, luteinizing hormone LH, sex hormone-binding globulin SHGB, FSH follicle-stimulating hormone. The mean level of testosterone was importantly boosted in VPA managed women at the time period of six months (p=0.03), the also at 12 th month (p=0.01). With the comparison of women of LTG and VPA group the measurement of hirsutism growth (p=0.06), disturbances in the menstrual cycle *(p=0.02) and PCOS (p=0.001). Long-term therapy of valproate in women suffered from epilepsy was linked with the connection of menstrual disturbance and increased PCOS risk development and also there are changes in reproductive hormonal function.